Yunchong Liu

Yunchong Liu

Auto-generated profile, based on publicly available information

Yunchong Liu

Department of Urology, Peking University Third Hospital, Beijing, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2024 in BMC Urology
Verified
Journal Article
Open access
PDF file
JCJiyuan Chen
Jiyuan Chen
ZLZhuo Liu
Zhuo Liu
RPRan Peng
Ran Peng
YLYunchong Liu
Yunchong Liu
HZHongxian Zhang
Hongxian Zhang
LMLulin Ma
Lulin Ma
Background: Surgical treatment for renal cell carcinoma (RCC) and inferior vena cava (IVC) tumor thrombus (TT) is difficult, and the postoperative complication rate is high. This study aimed to explore the safety and oncologic outcomes of neoadjuvant stereotactic ablative body radiotherapy (SABR) combined with surgical treatment for RCC and IVC-TT. Methods: Patients with RCC and IVC-TTs were enrolled in this study. All patients received neoadjuvant SABR focused on the IVC at a dose of 30 Gy in 5 fractions, followed by 2 ~ 4 weeks of rest. Then, radical nephrectomy and IVC tumor thrombectomy were performed for each patient. Adverse effects, perioperative outcomes, and long-term prognoses were recorded. Results: From June 2018 to January 2019, 8 patients were enrolled—4 with Mayo grade II TT and 4 with Mayo grade III TT. Four (50%) patients had complicated IVC wall invasion according to CT/MRI. All patients received neoadjuvant SABR as planned. Short-term local control was observed in all 8 patients. Only Grade 1–2 adverse events were reported. In total, 3 (37.5%) laparoscopic surgeries and 5 (62.5%) open surgeries were performed. The median operation time was 359 (IQR: 279–446) min, with a median intraoperative bleeding volume of 750 (IQR: 275–2175) ml. The median postoperative hospital stay was 7 (5–10) days. With a 26-month (range: 5–41) follow-up period, the estimated mean overall survival was 30.67 ± 5.38 months. Conclusions: This is the first preoperative radiotherapy study in Asia that focused on patients with TT. This study revealed the considerable safety of neoadjuvant SABR for RCC with IVC-TT. Trial registration: This study was registered in the Chinese Clinical Trials Registry on 2018-03-08 (ChiCTR1800015118). For more information, please see the direct link (https://www.chictr.org.cn/showproj.html?proj=25747).

31 January 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
YLYunchong Liu
Yunchong Liu
ZLZhuo Liu
Zhuo Liu
RPRan Peng
Ran Peng
RXRuotao Xiao
Ruotao Xiao
JWJunjie Wang
Junjie Wang
LMLulin Ma
Lulin Ma
Introduction Although surgery is currently the first choice for patients with renal cell carcinoma and vena cava tumour thrombus, the surgery is difficult, with many complications, and the prognosis of patients is not ideal. Renal cell carcinoma is not sensitive to traditional radiotherapy, but the development of stereotactic ablative body radiotherapy (SABR) technology with the characteristics of high precision, dose and conformity has made the radiotherapy of renal cell carcinoma reexamined. Study design This trial is a single-arm cohort study sponsored by Peking University Third Hospital. Study treatment Preoperative stereotactic ablative radiotherapy combined with surgical treatment. Primary endpoints (1) Adverse reactions after 4–6 weeks of SABR. (2) Mayo staging of tumour thrombus. (3) The length of the tumour thrombus from the corresponding anatomical mark. (4) Invasion of the inferior vena cava wall. (5) Recurrent-free survival rate of the tumour. (6) Cancer-specific survival rate. (7) Overall survival rate. (8) Perioperative indicators including operation time, intraoperative bleeding volume and postoperative complications. Secondary endpoints (1) The longest diameter of the tumour and (2) Lymph node condition. Main inclusion criteria Patients with renal cell carcinoma and inferior vena cava tumour thrombus graded from Mayo II to IV and eligible for radical nephrectomy and inferior vena cava thrombectomy. Main exclusion criteria Patients with previous targeted therapy, chemotherapy or other interventions, or who cannot tolerate SABR or surgery. Planned sample size 20 patients. Ethics and dissemination The trial protocol and the informed consent of the subjects were submitted and approved by the Peking University Biomedical Ethics Committee. Trial registration number ChiCTR1800015118.